(Sharecast News) - Shares in Abivax tanked on Tuesday, after trial results for an inflammatory bowel drug developed by the French biotech disappointed.
Obefazimod is an investigational oral treatment for adults with moderately to severe active ulcerative colitis (UC).

Publishing phase III results, Abivax said that at week 44, both...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE